Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total knee replacement: a randomized enoxaparin-controlled open label dose-escalation study.

Trial Profile

Factor Xa inhibitor YM150 for prevention of venous thromboembolism in patients undergoing elective total knee replacement: a randomized enoxaparin-controlled open label dose-escalation study.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2011

At a glance

  • Drugs Darexaban; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions
  • Acronyms PEARL-1
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 May 2009 Actual patient number (367) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top